MS lesions

FDA clears AI tool for detecting disease activity on MRI scans

Pixyl.Neuro, a next-generation software that uses artificial intelligence (AI) in analyzing MRI scans to help detect and monitor multiple sclerosis (MS) disease activity, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for clinical use. 510(k) clearance is required for medical devices used in the…

Need to Know: What Is an MS Mimic?

Editor’s note: “Need to Know” is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by the forum topic “Is it an MS Diagnosis or is it something else? ” from July…

My Unique Primary Progressive MS Diagnosis

I have lived with the diagnosis of primary progressive multiple sclerosis (PPMS) for almost eight years. For many years prior to that diagnosis, I was confused by what could be causing my abnormal gait, extreme fatigue, blurred vision, and trouble concentrating. During that time, I completed many diagnostic tests, dealt…

MS Study Finds Lipid Antibodies Reflect Changes in Brain Volume and Lesions

Brigham and Women’s Hospital researchers reported that antibodies directed at lipids are associated with magnetic resonance imaging (MRI) measures of brain degeneration in patients with multiple sclerosis (MS), and may potentially serve as biomarkers for monitoring disease status. While the hyperintense brain lesions detected by MRI are crucial for diagnosis and therapeutic…

Potential MS Biomarker Seen in Adipose Tissue Secretion

In a new study titled “Adipsin Is Associated with Multiple Sclerosis: A Follow-Up Study of Adipokines,” researchers report a correlation between an adipokine called adipsin and the pathogenesis of multiple sclerosis (MS). The study was published in the Multiple Sclerosis International journal. Obese adolescents…